Your browser doesn't support javascript.
loading
Clinical presentation and proteomic signature of patients with TANGO2 mutations.
Mingirulli, Nadja; Pyle, Angela; Hathazi, Denisa; Alston, Charlotte L; Kohlschmidt, Nicolai; O'Grady, Gina; Waddell, Leigh; Evesson, Frances; Cooper, Sandra B T; Turner, Christian; Duff, Jennifer; Topf, Ana; Yubero, Delia; Jou, Cristina; Nascimento, Andrés; Ortez, Carlos; García-Cazorla, Angels; Gross, Claudia; O'Callaghan, Maria; Santra, Saikat; Preece, Maryanne A; Champion, Michael; Korenev, Sergei; Chronopoulou, Efsthatia; Anirban, Majumdar; Pierre, Germaine; McArthur, Daniel; Thompson, Kyle; Navas, Placido; Ribes, Antonia; Tort, Frederic; Schlüter, Agatha; Pujol, Aurora; Montero, Raquel; Sarquella, Georgia; Lochmüller, Hanns; Jiménez-Mallebrera, Cecilia; Taylor, Robert W; Artuch, Rafael; Kirschner, Janbernd; Grünert, Sarah C; Roos, Andreas; Horvath, Rita.
Afiliação
  • Mingirulli N; Department of Neuropediatrics and Muscle Disorders, Medical Center - University of Freiburg, Faculty of Medicine, Breisgau, Germany.
  • Pyle A; Department of General Pediatrics, Adolescent Medicine and Neonatology, Medical Center - University of Freiburg, Faculty of Medicine, Breisgau, Germany.
  • Hathazi D; Wellcome Centre for Mitochondrial Research, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK.
  • Alston CL; Biomedical Research Department, Leibniz-Institut für Analytische Wissenschaften - ISAS - e.V, Dortmund, Germany.
  • Kohlschmidt N; Wellcome Centre for Mitochondrial Research, Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK.
  • O'Grady G; Institute of Clinical Genetics and Tumor Genetics, Bonn, Germany.
  • Waddell L; Kid's Neuroscience Centre, Children's Hospital at Westmead, Sydney, New South Wales, Australia.
  • Evesson F; Kid's Neuroscience Centre, Children's Hospital at Westmead, Sydney, New South Wales, Australia.
  • Cooper SBT; Kid's Neuroscience Centre, Children's Hospital at Westmead, Sydney, New South Wales, Australia.
  • Turner C; Discipline of Child and Adolescent Health, The University of Sydney, Sydney, New South Wales, Australia.
  • Duff J; Kid's Neuroscience Centre, Children's Hospital at Westmead, Sydney, New South Wales, Australia.
  • Topf A; Discipline of Child and Adolescent Health, The University of Sydney, Sydney, New South Wales, Australia.
  • Yubero D; Discipline of Child and Adolescent Health, The University of Sydney, Sydney, New South Wales, Australia.
  • Jou C; Cardiology, The Children's Hospital at Westmead, Sydney, New South Wales, Australia.
  • Nascimento A; Wellcome Centre for Mitochondrial Research, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK.
  • Ortez C; John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK.
  • García-Cazorla A; Department of Clinical Biochemistry, Genetics, Pediatric Neurology and Cardiology and Biobank, Institut de Recerca Sant Joan de Déu and CIBERER, Instituto de Salud Carlos III Barcelona, Barcelona, Spain.
  • Gross C; Department of Clinical Biochemistry, Genetics, Pediatric Neurology and Cardiology and Biobank, Institut de Recerca Sant Joan de Déu and CIBERER, Instituto de Salud Carlos III Barcelona, Barcelona, Spain.
  • O'Callaghan M; Department of Clinical Biochemistry, Genetics, Pediatric Neurology and Cardiology and Biobank, Institut de Recerca Sant Joan de Déu and CIBERER, Instituto de Salud Carlos III Barcelona, Barcelona, Spain.
  • Santra S; Department of Clinical Biochemistry, Genetics, Pediatric Neurology and Cardiology and Biobank, Institut de Recerca Sant Joan de Déu and CIBERER, Instituto de Salud Carlos III Barcelona, Barcelona, Spain.
  • Preece MA; Department of Clinical Biochemistry, Genetics, Pediatric Neurology and Cardiology and Biobank, Institut de Recerca Sant Joan de Déu and CIBERER, Instituto de Salud Carlos III Barcelona, Barcelona, Spain.
  • Champion M; Wellcome Centre for Mitochondrial Research, Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK.
  • Korenev S; Department of Clinical Biochemistry, Genetics, Pediatric Neurology and Cardiology and Biobank, Institut de Recerca Sant Joan de Déu and CIBERER, Instituto de Salud Carlos III Barcelona, Barcelona, Spain.
  • Chronopoulou E; Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK.
  • Anirban M; Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK.
  • Pierre G; Department of Inherited Disease, St Thomas Hospital, London, UK.
  • McArthur D; Department of Inherited Disease, St Thomas Hospital, London, UK.
  • Thompson K; South West Regional Metabolic Department, Bristol Royal Hospital for Children, Bristol, UK.
  • Navas P; South West Regional Metabolic Department, Bristol Royal Hospital for Children, Bristol, UK.
  • Ribes A; South West Regional Metabolic Department, Bristol Royal Hospital for Children, Bristol, UK.
  • Tort F; Center for Mendelian Genomics and Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Schlüter A; Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts.
  • Pujol A; Kid's Neuroscience Centre, Children's Hospital at Westmead, Sydney, New South Wales, Australia.
  • Montero R; Centro Andaluz de Biología del Desarrollo, Uníversidad Pablo de Olavide-CSIC-JA and CIBERER, Instituto de Salud Carlos III, Madrid, Spain.
  • Sarquella G; Secció d'Errors Congènits del Metabolisme - IBC, Servei de Bioquímica I Genètìca Molecular, Hospital Clínìc, IDIBAPS, CIBERER, Barcelona, Spain.
  • Lochmüller H; Secció d'Errors Congènits del Metabolisme - IBC, Servei de Bioquímica I Genètìca Molecular, Hospital Clínìc, IDIBAPS, CIBERER, Barcelona, Spain.
  • Jiménez-Mallebrera C; Neurometabolic Diseases Laboratory, Institut d'Investìgacío Biomedíca de Bellvitge (IDIBELL), and Centre for Biomedical Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
  • Taylor RW; Catalan Institution of Research and Advanced Studies (ICREA), Barcelona, Spain.
  • Artuch R; Department of Clinical Biochemistry, Genetics, Pediatric Neurology and Cardiology and Biobank, Institut de Recerca Sant Joan de Déu and CIBERER, Instituto de Salud Carlos III Barcelona, Barcelona, Spain.
  • Kirschner J; Department of Clinical Biochemistry, Genetics, Pediatric Neurology and Cardiology and Biobank, Institut de Recerca Sant Joan de Déu and CIBERER, Instituto de Salud Carlos III Barcelona, Barcelona, Spain.
  • Grünert SC; Department of Neuropediatrics and Muscle Disorders, Medical Center - University of Freiburg, Faculty of Medicine, Breisgau, Germany.
  • Roos A; Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, Ontario, Canada.
  • Horvath R; Division of Neurology, Department of Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada.
J Inherit Metab Dis ; 43(2): 297-308, 2020 03.
Article em En | MEDLINE | ID: mdl-31339582
ABSTRACT
Transport And Golgi Organization protein 2 (TANGO2) deficiency has recently been identified as a rare metabolic disorder with a distinct clinical and biochemical phenotype of recurrent metabolic crises, hypoglycemia, lactic acidosis, rhabdomyolysis, arrhythmias, and encephalopathy with cognitive decline. We report nine subjects from seven independent families, and we studied muscle histology, respiratory chain enzyme activities in skeletal muscle and proteomic signature of fibroblasts. All nine subjects carried autosomal recessive TANGO2 mutations. Two carried the reported deletion of exons 3 to 9, one homozygous, one heterozygous with a 22q11.21 microdeletion inherited in trans. The other subjects carried three novel homozygous (c.262C>T/p.Arg88*; c.220A>C/p.Thr74Pro; c.380+1G>A), and two further novel heterozygous (c.6_9del/p.Phe6del); c.11-13delTCT/p.Phe5del mutations. Immunoblot analysis detected a significant decrease of TANGO2 protein. Muscle histology showed mild variation of fiber diameter, no ragged-red/cytochrome c oxidase-negative fibers and a defect of multiple respiratory chain enzymes and coenzyme Q10 (CoQ10 ) in two cases, suggesting a possible secondary defect of oxidative phosphorylation. Proteomic analysis in fibroblasts revealed significant changes in components of the mitochondrial fatty acid oxidation, plasma membrane, endoplasmic reticulum-Golgi network and secretory pathways. Clinical presentation of TANGO2 mutations is homogeneous and clinically recognizable. The hemizygous mutations in two patients suggest that some mutations leading to allele loss are difficult to detect. A combined defect of the respiratory chain enzymes and CoQ10 with altered levels of several membrane proteins provides molecular insights into the underlying pathophysiology and may guide rational new therapeutic interventions.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Rabdomiólise / Encefalopatias Metabólicas / Debilidade Muscular / Doenças Mitocondriais / Proteômica / Mutação Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Female / Humans / Infant / Male Idioma: En Revista: J Inherit Metab Dis Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Rabdomiólise / Encefalopatias Metabólicas / Debilidade Muscular / Doenças Mitocondriais / Proteômica / Mutação Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Female / Humans / Infant / Male Idioma: En Revista: J Inherit Metab Dis Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Alemanha